Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06801236 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 1 study of Prostate Cancer (Adenocarcinoma) and mCRPC (Metastatic Castration-resistant Prostate Cancer), sponsored by Acerand Therapeutics (Hong Kong) Limited.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 67
- Enrollment target
- 8
- Study locations
NCT06801236: Recruiting Phase 1 study of Prostate Cancer (Adenocarcinoma) and mCRPC (Metastatic Castration-resistant Prostate Cancer), sponsored by Acerand Therapeutics (Hong Kong) Limited.
NCT06801236 is a Phase 1 study of Prostate Cancer (Adenocarcinoma) and mCRPC (Metastatic Castration-resistant Prostate Cancer) that is actively recruiting participants, run by Acerand Therapeutics (Hong Kong) Limited. The registered enrollment target is 67 participants, below the 125-participant average among 13 other Prostate Cancer (Adenocarcinoma) trials with a reported enrollment target (46% lower). The trial reports 8 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06801236, a Phase 1 study of Prostate Cancer (Adenocarcinoma) and mCRPC (Metastatic Castration-resistant Prostate Cancer), is actively recruiting participants, sponsored by Acerand Therapeutics (Hong Kong) Limited.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 67 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is an open label, phase I, multi-center study aiming to assess the safety and tolerability in patients with metastatic castration resistant prostate cancer (mCRPC).
Primary Outcome
Number of patients with incidence of adverse events and with serious adverse events including changes from baseline in laboratory parameters, vital signs, ECGs, and physical examination, etc.
Conditions Studied
Interventions
- DRUG ACE-232 tablets
Study Locations (8)
California
- University of California San Diego, Moores Cancer Center - La Jolla
Florida
- Moffitt Cancer Center, Tampa - Tampa
Maryland
- University of Maryland, Greenebaum Comprehensive Cancer Center - Baltimore
Massachusetts
- Harvard Medical School-Massachusetts General Hospital - Boston
Minnesota
- M Health Fairview Clinics and Surgery Center - Minneapolis
Nebraska
- Xcancer (Urology Cancer Center) - Omaha
South Carolina
- Carolina Urologic Research Center - Myrtle Beach
Washington
- Fred Hutchinson Cancer Research Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2025-05-12 |
| Est. Completion | 2028-08-01 |
| Phase | Phase 1 |
What NCT06801236 shows while recruiting
NCT06801236 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 67 participants, a relatively small participant target, below the 125-participant average among 13 other Prostate Cancer (Adenocarcinoma) trials with a reported enrollment target (46% lower).
The record links to 2 conditions, with Prostate Cancer (Adenocarcinoma) appearing as the primary indexed condition, and to 1 intervention - of which ACE-232 tablets is the first listed.
NCT06801236 lists 8 locations in 8 states (California, Florida, Maryland).
Frequently Asked Questions
What is clinical trial NCT06801236 about?
NCT06801236 is a clinical study titled "Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer". This is an open label, phase I, multi-center study aiming to assess the safety and tolerability in patients with metastatic castration resistant prostate cancer (mCRPC).
What is the current status of trial NCT06801236?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 67 participants. The study started on 2025-05-12. Estimated completion is 2028-08-01.
What conditions does trial NCT06801236 study?
This clinical trial studies the following conditions: Prostate Cancer (Adenocarcinoma), mCRPC (Metastatic Castration-resistant Prostate Cancer).
What interventions are being tested in trial NCT06801236?
The interventions under investigation include: ACE-232 tablets (DRUG).
Who is sponsoring clinical trial NCT06801236?
This trial is sponsored by Acerand Therapeutics (Hong Kong) Limited, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06801236 being conducted?
This trial has 8 study locations across California, Florida, Maryland, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer (Adenocarcinoma)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06801236's enrollment target sits among peer trials
67 6th of 13 higher than 8 of 13 other Prostate Cancer (Adenocarcinoma) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer (Adenocarcinoma) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer
RECRUITING · Phase 1
-
A Study of HLD-0915 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
RECRUITING · Phase 1
-
Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer
RECRUITING · Phase 1
-
PSMA PET for Surveillance After Focal Therapy
RECRUITING · NA
-
FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Flotufolastat F 18 PET in Men With Very Low PSA Recurrence
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03213002 · 67 participants · Phase 1
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
- NCT04115163 · 67 participants · Phase 2
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
- NCT04315324 · 67 participants · Phase 1
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
- NCT04532424 · 67 participants · NA
Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI